Sebree Terri B's Form 4 filing
Zynerba Pharmaceuticals, Inc. (ZYNE) · filed Sep 14, 2023
- Accession no.
- 0001062993-23-018022
- Filed
- Sep 14, 2023
- Trade date
- Sep 12-13, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $16.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sebree Terri BCIK 0001297912 | Officer (President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2023 | Common Stock | AGrant or awardAcquired | +45,000 | –F1 | – | 608,642 | Direct | |
| Sep 13, 2023 | Common Stock | SSaleDisposed | −12,401 | $1.33 | −$16,493.33 | 596,241 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 45,000 performance-based restricted stock awards granted in a prior year.
Referenced by the price of 1 transaction in Table I.